Why the study?
Are alternative biomarkers superior or additive to high-sensitive cardiac troponin for the early diagnosis of myocardial infarction?
Population
Patients with suspected acute coronary syndrome and myocardial infarction
Comparison
High-sensitive cardiac troponin (hs-cTn) assays vs Alternative or traditional biomarkers
Design
Review
Authors
Loading...
hs-cTn remains the diagnostic standard for AMI; leaves open whether novel markers add value in early rule-out.
Are alternative biomarkers superior or additive to high-sensitive cardiac troponin for the early diagnosis of myocardial infarction?
High-sensitive cardiac troponin remains the superior biomarker for diagnosing acute myocardial infarction, with alternative markers offering little to no incremental diagnostic value.
Karl J. Lackner (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: